Close Menu

Benitec

The company also announced deals for new DNA production and delivery technologies.

NEW YORK (GenomeWeb) – Benitec Biopharma this week announced that it has licensed its expressed RNAi technology to Circuit Therapeutics for the development of an intractable pain treatment.

NEW YORK (GenomeWeb) – Benitec Biopharma said this week that laboratory data on the first patient dosed in its Phase I/IIa trial its expressed RNAi treatment for hepatitis C indicate that the drug is safe and well tolerated.

NEW YORK (GenomeWeb) – Benitec Biopharma this week announced that it is appealing the European Patent Office's recent revocation of a patent covering the company's core expressed RNAi technology, which had been successfully challenged by biotech firm Galapagos and agro-chemical giant BASF.

NEW YORK (GenomeWeb) – Benitec Biopharma last week disclosed delays in its efforts to dose patients in a Phase I/IIa trial of its expressed RNAi-based hepatitis C treatment TT-034 and said that it is taking steps to speed subject enrollment.

Biotech firm Amarantus Bioscience has appointed Iain Ross to its board of directors.

NEW YORK (GenomeWeb) – With more interest from industry and investors than ever before, the RNAi therapeutics field has a record number of drug candidates in human testing for indications ranging from viral disease to cancer to skin disorders.

NEW YORK (GenomeWeb) – Just months after disclosing that it is reestablishing its American footprint with a laboratory in Northern California, Australia's Benitec Biopharma announced that it has formally arranged for its stock to be traded in the US on the over-the-counter (OTC) market.

NEW YORK (GenomeWeb) – Benitec Biopharma last week announced that the European Patent Office has upheld its previous decision to revoke one of the company's core patents based on opposition filed by biotech firm Galapagos and chemical giant BASF.

NEW YORK (GenomeWeb) – Amid a recent downturn among biotechnology stocks, shares of the top eight publicly traded RNAi and microRNA drug developers have fared particularly poorly, shedding an average of 37 percent of their value from their year-to-date highs.

Pages

Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.

Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.

Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.

In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.